SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Single Photon Emission Computed Tomography Market Size and Trends

Global single photon emission computed tomography market is estimated to be valued at USD 3.13 Bn in 2024 and is expected to reach USD 4.87 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

To learn more about this report, request sample copy

The single photon emission computed tomography market is anticipated to demonstrate positive growth trajectory during the forecast period. Factors such as favorable reimbursement policies, technological advancements for better image quality and shorter scan time, increasing public-private investments for medical equipment and facilities, growing awareness about early disease diagnosis are expected to boost demand for SPECT devices. However, higher cost of equipment and procedure in comparison to other modalities and better accuracy of hybrid PET may restrain the market growth.

Increasing Role of Diagnostic Imaging in Drug Development

Global single photon emission computed tomography market is expected to grow significantly owing to increasing role of diagnostic imaging modalities such as SPECT in drug development and research activities. Pharmaceutical companies are exploring various imaging techniques to gain deeper insights into drug mechanisms and their effects on the human body. SPECT provides detailed functional information regarding drug distribution and target engagement in vivo, which helps researchers evaluate drug candidates at a very early stage. This early assessment allows them to eliminate non-viable compounds from the pipeline and focus resources on molecules with the highest chances of success. Researchers are able to see whether the drug reaches its intended target and verify, if engagement results in the desired downstream effects. Any safety issues can be identified early. Such quantitative and qualitative data obtained from SPECT and other molecular imaging techniques enables go/no-go decisions much before entering costly and time-consuming clinical trials. This greatly improves productivity in drug development by minimizing failures in late stages. Pharmaceutical companies are increasingly relying on molecular imaging to the risk candidates and extract maximum information from limited preclinical studies.

The growth in neurological disorders and cardiovascular diseases worldwide has translated to higher demand for diagnostic procedures that can accurately detect the presence and extent of such conditions. SPECT provides detailed functional information about perfusion and metabolic activity within brain and heart tissues, which is invaluable for differential diagnosis and treatment management of various neurological and cardiac pathologies. It allows visualization of subtle changes not seen on conventional imaging like CT or MRI, thereby facilitating early and more effective clinical intervention. Diseases like Alzheimer's and dementia are rising rapidly as the geriatric population expands globally. Brain SPECT scans can identify signs of neurodegeneration years before symptoms appear by tracking declines in regional cerebral blood flow patterns. In cardiology, SPECT myeloscintigraphy evaluate ischemic areas within the heart muscle in conditions like Coronary Artery Disease. It also aids in diagnosis of less common cardiac involvements like sarcoidosis, amyloidosis and cardiomyopathy. Given the growing burden of these diseases, healthcare providers are relying more on functional imaging modalities like SPECT to improve diagnostic accuracy and optimize care.